CG400549
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CG400549, covering 2013-05-07 to 2022-07-06. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus [Phase 2]